Skip to ContentSkip to Navigation
Practical matters How to find us dr. A.J. van der Wekken

Publications

Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial

The additional diagnostic value of virtual bronchoscopy navigation in patients with pulmonary nodules: The NAVIGATOR study

Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature

Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort

High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial

Molecular imaging to support cancer immunotherapy

Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer

Pharmacokinetically guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patients

Pharmacokinetically-guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patients

Predictive testing in stage-IV NSCLC within a network of collaborating hospitals

Read more

Press/media

Doelgerichte therapie bij longkanker

Actionabiliteit van on-target ALK-resistentiemutaties in niet-kleincellig longcarcinoom

Longkanker: welke vorm heb ik?

Plasma testing

Longkanker in Perspectief

Oncologie longkanker special

Magazine Longkanker

NOS journaal

RTV noord journaal

Read more